{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T20:03:02Z","timestamp":1776542582779,"version":"3.51.2"},"reference-count":10,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2021,3,2]]},"DOI":"10.1001\/jama.2020.19313","type":"journal-article","created":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T16:39:19Z","timestamp":1614703159000},"page":"878","source":"Crossref","is-referenced-by-count":11,"title":["Diagnosis and Treatment of Nonscarring Hair Loss in Primary Care in 2021"],"prefix":"10.1001","volume":"325","author":[{"given":"Paradi","family":"Mirmirani","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"},{"name":"Department of Dermatology, The Permanente Medical Group, Vallejo, California"},{"name":"Department of Dermatology, Case Western Reserve University, Cleveland, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California, San Francisco"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"4","key":"jit200031r1","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1001\/jamadermatol.2015.4498","article-title":"Cutaneous findings and systemic associations in women with polycystic ovary syndrome.","volume":"152","author":"Schmidt","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"1","key":"jit200031r2","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jaad.2017.02.054","article-title":"The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis.","volume":"77","author":"Adil","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"jit200031r4","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1001\/archderm.1993.01680240096017","article-title":"Telogen effluvium: new concepts and review.","volume":"129","author":"Headington","year":"1993","journal-title":"Arch Dermatol"},{"issue":"3","key":"jit200031r5","doi-asserted-by":"publisher","first-page":"e411","DOI":"10.1016\/j.jaad.2014.04.070","article-title":"Evaluation and diagnosis of the hair loss patient: part I: history and clinical examination.","volume":"71","author":"Mubki","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"jit200031r6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.det.2012.08.007","article-title":"How to diagnose hair loss.","volume":"31","author":"Jackson","year":"2013","journal-title":"Dermatol Clin"},{"issue":"4","key":"jit200031r7","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1038\/jid.2013.464","article-title":"Lifetime incidence risk of alopecia areata estimated at 2.1% by Rochester Epidemiology Project, 1990-2009.","volume":"134","author":"Mirzoyev","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"16","key":"jit200031r8","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1056\/NEJMra1103442","article-title":"Alopecia areata.","volume":"366","author":"Gilhar","year":"2012","journal-title":"N Engl J Med"},{"issue":"3","key":"jit200031r9","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/dth.2011.24.issue-3","article-title":"Investigative guidelines for alopecia areata.","volume":"24","author":"Olsen","year":"2011","journal-title":"Dermatol Ther"},{"issue":"9","key":"jit200031r10","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1016\/j.jid.2018.05.027","article-title":"JAK inhibitors for treatment of alopecia areata.","volume":"138","author":"Wang","year":"2018","journal-title":"J Invest Dermatol"},{"key":"jit200031r3","unstructured":"Highlights of prescribing information: PROPECIA. US Food and Drug Administration. Updated September 2013. Accessed July 6, 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020788s020s021s023lbl.pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2776865\/jama_mirmirani_2021_it_200031_1614619877.25242.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T16:39:25Z","timestamp":1614703165000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2776865"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,2]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,3,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2020.19313","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3,2]]}}}